The possible link between prostate cancer treatment and dementia is a topic that has been making quite a few headlines over the last several weeks. According to a recent Penn Medicine News Release that seems to have started the conversation, researchers at the University of Pennsylvania have found that “a common hormone therapy [used] to treat prostate cancer may double a man’s risk of dementia, regardless of his age.”
Last year, lead author Kevin T. Nead, MD, MPhil, a resident in the department of Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania, and his colleagues discovered an association between Alzheimer’s disease and androgen deprivation therapy (ADT) — a treatment for prostate cancer that is used in over half a million men in the U.S. However, the new findings, published in JAMA Neurology, lead them to believe that the neurocognitive risk involved is actually broader than just Alzheimer’s.
As stated in the news release, “while the findings do not prove that ADT increases the risk of dementia, the analysis comparing the medical records of almost 9,500 prostate cancer patients who received ADT vs. those who did not strongly supports that possibility.”
“We have two papers here showing very similar outcomes and magnitude of risk, which I think supports the case for this to be studied prospectively,” explained Dr. Nead.
This raises the question – do the benefits of ADT outweigh the risk of dementia?
In a recent feature in NY Times Well, Dr. Nead addressed this question explaining that this is a discussion that patients should have with their physician. “This study is important and urges us toward future research, but I don’t think it should impact clinical practice,” he said.
Read the full Penn Medicine News Release here.
Several other local and national news outlets have also picked up the story including